Importantly, the relationship of electrophysiological analysis and use of neuroimaging (e.g., DTI, MRI) and molecular biomarkers (e.g., NfL) is standardizing the recent advances of precision medicine in ALS and potentially real-time therapeutic ratification [123]. Here, NEFL is linked to amyotrophic lateral sclerosis.